#1 Clinical Trials Search in Europe

Toldc

Tolerogenic Dendritic Cells (TolDC), also known as “Toldc,” are being studied in clinical trials as a potential treatment for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. These trials aim to evaluate the safety, feasibility, and potential effectiveness of TolDC therapy in managing these conditions. The research involves using the patient’s own cells to create a personalized treatment that may help regulate the immune system and reduce inflammation.

Table of Contents

What is TOLDC?

TOLDC, which stands for Tolerogenic Dendritic Cells, is an innovative experimental treatment being studied for autoimmune diseases[1][2]. This therapy uses a patient’s own cells, specifically a type of white blood cell called dendritic cells, which have been modified to help regulate the immune system. The goal of TOLDC is to “teach” the immune system to tolerate the body’s own tissues, potentially reducing inflammation and disease activity in autoimmune conditions.

How Does TOLDC Work?

TOLDC works by modifying the patient’s own dendritic cells to become “tolerogenic,” meaning they can promote tolerance in the immune system. Here’s a simplified explanation of the process:

  1. Cell collection: White blood cells are collected from the patient through a procedure called leukapheresis[1].
  2. Cell modification: The collected cells are processed in a laboratory to create tolerogenic dendritic cells. In some cases, they may be treated with vitamin D3 and loaded with specific proteins (peptides) related to the disease being treated[2].
  3. Administration: The modified cells are then given back to the patient, usually by injection into a joint or lymph node[1][2].
  4. Immune regulation: Once in the body, these cells are designed to interact with other immune cells, potentially reducing harmful inflammation and autoimmune responses.

What Conditions Can TOLDC Potentially Treat?

Current clinical trials are exploring the use of TOLDC for two main autoimmune conditions:

  • Rheumatoid Arthritis (RA): A chronic inflammatory disorder that primarily affects joints[1].
  • Multiple Sclerosis (MS): A condition where the immune system attacks the protective covering of nerves. Two types of MS are being studied:
    • Relapsing-Remitting MS
    • Chronic Progressive MS[2]

How is TOLDC Administered?

The administration of TOLDC varies depending on the condition being treated and the specific clinical trial:

  • For Rheumatoid Arthritis: TOLDC is injected directly into an affected knee joint using a procedure called arthroscopy (a minimally invasive surgical technique that uses a camera to see inside the joint)[1].
  • For Multiple Sclerosis: TOLDC is administered through intranodal injection, which means it’s injected directly into lymph nodes in the neck area[2].

Current Clinical Trials

Two main clinical trials are currently investigating TOLDC:

  1. AutoDECRA trial for Rheumatoid Arthritis: This Phase 1 study aims to treat 12 patients with RA, with 9 receiving TOLDC and 3 receiving a control treatment. The study will test three different doses of TOLDC[1].
  2. TOLERVIT-MS trial for Multiple Sclerosis: This is a Phase 1 dose-ascending trial for MS patients. It will test three different doses of TOLDC (5 million, 10 million, and 15 million cells) and will also include a group of patients who are already being treated with beta-interferon, another MS medication[2].

Safety and Efficacy

As TOLDC is still in early-stage clinical trials, its safety and efficacy are not yet fully established. The primary goals of these studies include:

  • Assessing the safety and tolerability of TOLDC[1][2].
  • Monitoring for any adverse events or side effects[1][2].
  • Evaluating the feasibility of producing and administering TOLDC[1][2].
  • Looking for preliminary signs of effectiveness, such as changes in disease activity or improvements in symptoms[1][2].

Future Prospects

While TOLDC is still in the early stages of research, it represents an exciting new approach to treating autoimmune diseases. If proven safe and effective, it could offer several potential advantages:

  • A more targeted approach to regulating the immune system
  • Potentially fewer side effects than current immunosuppressive treatments
  • A personalized treatment using the patient’s own cells

However, it’s important to note that much more research is needed before TOLDC could become an approved treatment. The current clinical trials will help determine if larger, more advanced studies should be conducted in the future.

Aspect Rheumatoid Arthritis Trial Multiple Sclerosis Trial
Treatment Autologous TolDC Autologous TolDC-VitD3
Administration Method Intra-articular (knee joint) Intranodal (cervical lymph nodes)
Number of Participants 12 (9 TolDC, 3 control) Multiple cohorts with different doses
Duration Approximately 13 weeks 6 cycles over several months
Primary Outcomes Safety, feasibility, acceptability Safety, tolerability, neurologic changes
Secondary Outcomes Disease activity, immune system effects Relapse rate, disability progression, MRI changes

FAQ

  • What are Tolerogenic Dendritic Cells (TolDC)? Tolerogenic Dendritic Cells (TolDC) are a type of white blood cell that has been modified to potentially help regulate the immune system. They are created from the patient's own cells and are being studied as a possible treatment for autoimmune diseases.
  • How are TolDC administered in clinical trials? In the trials mentioned, TolDC are administered in different ways depending on the condition being treated. For rheumatoid arthritis, they are injected directly into the knee joint during a procedure called arthroscopy. For multiple sclerosis, they are injected into lymph nodes in the neck.
  • What conditions are being studied with TolDC therapy? The clinical trials mentioned are studying TolDC therapy for rheumatoid arthritis and multiple sclerosis, both of which are autoimmune diseases where the immune system mistakenly attacks the body's own tissues.
  • What are the main goals of these TolDC clinical trials? The main goals of these trials are to assess the safety and tolerability of TolDC therapy, determine the feasibility of producing and administering the treatment, and gather preliminary data on its potential effectiveness in managing the symptoms of autoimmune diseases.
  • How long do the TolDC clinical trials last? The duration of the trials varies. For the rheumatoid arthritis study, patients are followed for about 13 weeks. The multiple sclerosis study involves six treatment cycles over several months, with follow-up assessments to monitor safety and potential effects.

Ongoing Clinical Trials on Toldc

  • Study of the safety and effectiveness of tolDC therapy in patients with progressive forms of multiple sclerosis

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Spain

  • Study on the Safety and Effectiveness of tolDC for Patients with Relapsing Remitting and Progressive Multiple Sclerosis

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Spain

Glossary

  • Tolerogenic Dendritic Cells (TolDC): A type of white blood cell that has been modified to potentially help regulate the immune system and reduce inflammation in autoimmune diseases.
  • Arthroscopy: A minimally invasive surgical procedure that uses a small camera to examine the inside of a joint, such as the knee.
  • Leukapheresis: A medical procedure that involves removing white blood cells from a patient's blood, which can then be used to create personalized treatments like TolDC.
  • Rheumatoid Arthritis (RA): An autoimmune disease that causes inflammation, pain, and stiffness in the joints, particularly in the hands and feet.
  • Multiple Sclerosis (MS): A chronic autoimmune disease that affects the central nervous system, causing a wide range of symptoms including fatigue, difficulty walking, and vision problems.
  • Intranodal administration: A method of delivering treatment directly into lymph nodes, which are part of the body's immune system.
  • GMP-grade: Refers to products manufactured according to Good Manufacturing Practice standards, ensuring high quality and safety for use in patients.
  • DAS28: Disease Activity Score using 28 joints, a measure used to assess the activity of rheumatoid arthritis.
  • EDSS: Expanded Disability Status Scale, a method of measuring disability in multiple sclerosis.
  • MRI: Magnetic Resonance Imaging, a non-invasive imaging technique used to visualize internal body structures, often used in MS to detect brain lesions.

References

  1. https://clinicaltrials.gov/study/NCT01352858
  2. https://clinicaltrials.gov/study/NCT02903537